Taisho Pharmaceutical Holdings Co., Ltd.
TAISF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $684 | $500 | $449 | $453 |
| - Cash | $246 | $240 | $248 | $256 |
| + Debt | $9 | $6 | $6 | $3 |
| Enterprise Value | $447 | $265 | $207 | $199 |
| Revenue | $84 | $82 | $81 | $74 |
| % Growth | 1.6% | 1.8% | 9.6% | – |
| Gross Profit | $46 | $47 | $48 | $41 |
| % Margin | 55.6% | 57% | 59.8% | 56.3% |
| EBITDA | $15 | $7 | $13 | $1 |
| % Margin | 18.1% | 8.2% | 16.5% | 1.4% |
| Net Income | $3 | $3 | $4 | -$2 |
| % Margin | 3.4% | 3.8% | 5.4% | -2.6% |
| EPS Diluted | 35 | 37.6 | 53.15 | -23.2 |
| % Growth | -6.9% | -29.3% | 329.1% | – |
| Operating Cash Flow | $21 | $15 | $14 | $13 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $21 | $15 | $14 | $13 |